Research gapMedicine & healthcare

Taking blood pressure medicines as prescribed: why decades of adherence research have not closed the control gap

Around a third of people treated for hypertension do not take their medicines as prescribed, and the rate did not fall between 2010 and 2020 (Lee et al., 2022). Hundreds of trials and several layers of systematic reviews exist, yet no intervention reliably works at scale (Nieuwlaat et al., 2014; Mackridge et al., 2025).

PhD Research Lab InsightsEditorial team, reviewed by a subject specialist
Posted
5 October 2026
Last checked
5 October 2026
Reading time
10 min
Sources
9
Research proposal support
The gap

We still do not know which adherence interventions, delivered in routine primary care and at a cost health systems can sustain, produce lasting improvements in both medicine-taking and blood pressure control, particularly in low- and middle-income settings where non-adherence is most common (Lee et al., 2022; Aminde et al., 2025). Trials report modest and inconsistent effects (Nieuwlaat et al., 2014; Wilhelmsen & Eriksson, 2019), and adherence itself is measured in ways that do not agree (Lee et al., 2022; Rabbitt et al., 2024).

Implementation gapEvidence gap (inconsistent effects)Methodological gap (measurement)Population and setting gap

What we know

  • Across 161 studies in 68 countries (about 27.8 million patients), 27% to 40% of people with hypertension were non-adherent, depending on how adherence was measured; there was no significant trend between 2010 and 2020 (Lee et al., 2022).
  • Non-adherence is more common in low- and middle-income and non-Western regions, and is linked to higher blood pressure and greater odds of poor control and hospitalisation (Lee et al., 2022).
  • In sub-Saharan Africa, 43.9% of treated adults were non-adherent across 95 studies (34,102 people, 27 countries), with no change over almost three decades (Aminde et al., 2025).
  • A Cochrane review of 182 randomised trials found that only five of the 17 highest-quality trials improved both adherence and clinical outcomes, and no common feature explained their success (Nieuwlaat et al., 2014).
  • Overviews of reviews find modest benefits for education, counselling, simpler regimens and pharmacist- or nurse-led support, but no single strategy that works in all settings (Wilhelmsen & Eriksson, 2019; Mackridge et al., 2025).
  • Patients describe barriers that are practical as well as personal: medication literacy, fear of side effects, cost, access to care and forgetfulness (Zhou et al., 2024).

What we do not know yet

  • Which combinations of intervention components drive the modest effects seen in trials, and for which patients.
  • Whether effects shown in trials last beyond the usual short follow-up and survive scale-up in routine primary care.
  • How to measure adherence in everyday practice in a way that is accurate, affordable and agreed across studies.
  • Which approaches work in low-income settings, where medicine supply and access are themselves barriers.
  • Whether objective adherence testing, fed back to patients, changes long-term outcomes rather than only detection.

Research questions a PhD could ask

  1. Which components of multicomponent adherence interventions (pharmacist follow-up, regimen simplification, reminders, feedback) explain improvements in blood pressure control in primary care?
  2. Do adherence gains achieved in trials persist at 12 and 24 months when interventions are delivered by routine health-system staff?
  3. How well do self-report, pharmacy refill and chemical adherence testing agree, and which is practical in resource-limited clinics?
  4. In sub-Saharan African primary care, which patient-level and system-level factors best predict non-adherence, and which can a service realistically change?
  5. Does sharing chemical adherence test results with patients improve blood pressure control compared with usual care?
Methods that could close the gap
ApproachWhy it fits
Component network meta-analysisSeparates the contribution of individual intervention components across the large trial base summarised by Nieuwlaat et al. (2014) and Mackridge et al. (2025).
Pragmatic or cluster randomised trialTests a defined intervention in routine primary care with longer follow-up, answering the scale-up question that overviews of reviews leave open (Wilhelmsen & Eriksson, 2019).
Measurement comparison studyCompares self-report, refill data and chemical testing in the same patients, responding to the variation in methods noted by Lee et al. (2022) and Rabbitt et al. (2024).
Qualitative or mixed-methods process evaluationExplains why interventions work or fail for particular patients, building on the barriers synthesised by Zhou et al. (2024).
Secondary analysis of cohort or registry dataTracks adherence trajectories and outcomes over years where prescription and refill records exist, extending trend analyses (Aminde et al., 2025).
Gap typeHeavily researched, still unsolved

The problem

Many people prescribed blood pressure medicines do not start, take or continue them as agreed with their clinician. Pooled estimates put non-adherence at 27% to 40% worldwide, and it is associated with higher blood pressure and poorer control (Lee et al., 2022).

Why it happens

Non-adherence has several causes acting together: limited understanding of a symptomless condition, reluctance to accept a long-term diagnosis, fear of side effects, cost, distance from care and simple forgetting (Zhou et al., 2024). Health systems add their own barriers, including medicine shortages in low-income countries (World Health Organization, 2025).

Where it is felt most

The burden is greatest in low- and middle-income countries and in non-Western regions (Lee et al., 2022), with sub-Saharan Africa showing high and unchanging rates (Aminde et al., 2025; Apostolou et al., 2026). It is felt most in primary care, where long-term treatment is managed.

How big is the problem

  • 1.4 billionpeople living with hypertension worldwide in 2024; just over one in five have it under control (WHO, 2025) (World Health Organization, 2025)
  • 27% to 40%global prevalence of non-adherence to antihypertensive medicines, depending on measurement method, 161 studies, 2010 to 2020 (Lee et al., 2022)
  • 43.9%pooled non-adherence among treated adults in sub-Saharan Africa, 95 studies, 34,102 people, 1995 to 2023 (Aminde et al., 2025)
  • 99 of 195countries and territories with hypertension control rates below 20% (WHO, 2025) (World Health Organization, 2025)
What studies say, and at what level of evidence
LevelWhat it shows
Systematic reviews and meta-analysesNon-adherence is common and stable over time worldwide (Lee et al., 2022) and in sub-Saharan Africa (Aminde et al., 2025); adherence to antihypertensive medicines in that region pools at 51% (Apostolou et al., 2026).
Reviews of trialsAcross 182 trials, effects were modest and inconsistent; even the most effective interventions did not produce large improvements (Nieuwlaat et al., 2014).
Overviews and umbrella reviewsPharmacist-led and face-to-face support, combination tablets, reminders and feedback show benefit, but evidence is at risk of bias and comparisons between approaches are lacking (Wilhelmsen & Eriksson, 2019; Mackridge et al., 2025).
Qualitative evidenceA synthesis of 27 qualitative studies identifies knowledge, beliefs and social support as facilitators, and cost, access and fear of side effects as barriers (Zhou et al., 2024).
Measurement studiesChemical adherence testing has been studied in 48 papers, mostly observational, with only one randomised trial and varied thresholds (Rabbitt et al., 2024).
What is missingLong-term pragmatic trials in routine primary care in low- and middle-income countries, using agreed adherence measures and reporting blood pressure control as the main outcome.

Who should take this on

Scholar profile

  • A pharmacist or nurse with access to primary care clinics and dispensing records.
  • A clinician-researcher in a hypertension or non-communicable disease programme able to run a pragmatic trial.
  • A health psychologist or behavioural scientist interested in habit, beliefs and adherence.
  • A public health or health services researcher with skills in evidence synthesis or routine data analysis.

Subjects and PhD specialisations

  • Clinical pharmacy and pharmacy practice
  • Public health and epidemiology
  • Health psychology
  • Nursing and primary care
  • Health services research
  • Cardiovascular medicine

Countries where the problem is greatest

  • Sub-Saharan Africa: non-adherence of 43.9% with no change over time (Aminde et al., 2025), and low adherence across treatment and self-care for hypertension and diabetes (Apostolou et al., 2026).
  • Low-income countries generally: only 28% report general availability of all WHO-recommended hypertension medicines, against 93% of high-income countries (World Health Organization, 2025).
  • Low- and middle-income and non-Western regions: higher non-adherence than high-income and Western regions (Lee et al., 2022).
  • Bangladesh and the Republic of Korea: WHO reports large gains in control, which make them useful comparison settings for what works (World Health Organization, 2025).

Scope for future research

  1. Component-level synthesis of the adherence trial literature to identify active ingredients.
  2. Pragmatic trials of pharmacist- or nurse-led models embedded in public primary care, with follow-up of two years or more.
  3. Agreed, low-cost adherence measures for routine practice, validated against chemical testing.
  4. Interventions that target system barriers (supply, cost, travel) alongside patient behaviour.
  5. Adherence across conditions, since many patients take medicines for both hypertension and type 2 diabetes (Apostolou et al., 2026).

How a doctoral project could address it

  1. Define

    Narrow the question to one population, setting and adherence behaviour (initiation, implementation or persistence), and type the gap explicitly.

  2. Synthesise

    Start with a focused review that maps trials by component and setting, updating the existing reviews (Nieuwlaat et al., 2014; Mackridge et al., 2025).

  3. Design

    Choose a feasible design: a pilot or cluster trial, a measurement comparison, or a cohort analysis of refill records.

  4. Data and partners

    Agree access with clinics, pharmacies or a national programme early, including how blood pressure and adherence will be recorded.

  5. Ethics

    Plan consent, data protection and how results from adherence tests will be shared with patients without blame.

  6. Outputs

    Aim for a review paper, a protocol, a main results paper and a process evaluation, which together can form the thesis.

Why it is worth solving

WHO estimates that only just over one in five people with hypertension have it under control, and that strokes and heart attacks from high blood pressure cost over 1,000 lives every hour (World Health Organization, 2025). Effective medicines already exist; a large part of the shortfall lies in whether people can obtain them and keep taking them (Lee et al., 2022; World Health Organization, 2025).

Solving even part of this problem would benefit patients, reduce avoidable hospital admissions and help health systems get value from medicines they already buy. For science, it would show which parts of complex behavioural interventions actually work, a question the large trial literature has not answered (Nieuwlaat et al., 2014).

Why so much research has not solved it

Adherence has been studied for decades, and the Cochrane review alone brings together 182 randomised trials (Nieuwlaat et al., 2014). The problem is not a lack of studies but the kind of evidence they produce. Most interventions are complex, combining education, counselling, reminders and follow-up, so it is hard to tell which part made the difference. The review authors found no common characteristic among the few trials that improved both adherence and clinical outcomes, and concluded that it remains uncertain how adherence can be improved consistently (Nieuwlaat et al., 2014).

Later overviews reach a similar position. Some approaches, such as pharmacist- or nurse-led support and simpler regimens, show benefit, yet no single strategy works in every setting (Wilhelmsen & Eriksson, 2019). A 2025 umbrella review identified eight promising approaches but noted risk of bias and a lack of head-to-head comparisons (Mackridge et al., 2025). Meanwhile, the global prevalence of non-adherence did not change between 2010 and 2020 (Lee et al., 2022).

Where a doctoral project can add value

A PhD cannot solve non-adherence, but it can close a defined part of the gap. Three angles are realistic. The first is analytical: re-examining the trial literature by component and setting to identify which ingredients matter. The second is methodological: testing how well cheap adherence measures agree with objective testing in a real clinic. The third is applied: a pilot or feasibility trial of a clearly specified intervention in primary care, with a process evaluation that explains the result.

Realistic doctoral angles on hypertension adherence
AngleTypical dataMain skill
Evidence synthesisPublished trials and reviewsSystematic review and meta-analysis
Measurement studySelf-report, refill and chemical test results from one cohortAgreement statistics
Pilot or feasibility trialClinic records, blood pressure readings, interviewsTrial design and mixed methods
Routine data analysisPrescription and refill recordsLongitudinal modelling

Patient voice matters in all of them. The barriers people describe, from cost to fear of side effects (Zhou et al., 2024), should shape what is tested, not only how results are explained.

What to do now

  • Read the Cochrane review and the two overviews first, and note which components and settings they cover (Nieuwlaat et al., 2014; Wilhelmsen & Eriksson, 2019; Mackridge et al., 2025).
  • Decide which adherence behaviour and which measure your project will use, and justify the choice.
  • Contact a clinic, pharmacy or programme about data access before fixing your design.
  • Write a one-paragraph gap statement and test it with your supervisor before drafting research questions.
Your next step

Could this gap become your thesis?

  1. 1Read the evidence and the open questions
  2. 2Talk to a mentor about fit, data and method
  3. 3Build a defensible proposal
See proposal support

Questions scholars ask

With 182 trials already, is there anything left to study?

Yes. The trials show that effects are modest and inconsistent (Nieuwlaat et al., 2014); what is missing is evidence on which components work, for whom, and whether effects last in routine care.

Do I need to run a full randomised trial?

No. A synthesis, a measurement study or a well-designed pilot can each make an original contribution within a doctorate, provided the question is focused.

Is this topic only for clinicians?

No. Pharmacists, nurses, psychologists and public health researchers all work on adherence, and supervision across disciplines is common.

Which countries offer the strongest case for a study?

Settings with high, unchanging non-adherence, such as much of sub-Saharan Africa (Aminde et al., 2025), or settings where control has improved quickly (World Health Organization, 2025), both make strong cases.

Sources

  1. Aminde, L., Agbor, V., Fongwen, N. T., Ngwasiri, C. A., Nkoke, C., Nji, M. A., Dzudie, A., & Schutte, A. E. (2025). High burden and trend in nonadherence to blood pressure-lowering medications: Meta-analysis of data from over 34 000 adults with hypertension in sub-Saharan Africa. Journal of the American Heart Association, 14(9), e037555. https://doi.org/10.1161/JAHA.124.037555
  2. Apostolou, A., Simfukwe, R., Saint, A., Mushani, B., Chekhchar, H., Aovare, P., Agboyibor, K. M., Meeks, K. A. C., Mkoma, G. F., Agyemang, C., & Chilunga, F. P. (2026). Adherence to medications, lifestyle advice, and self-monitoring for type 2 diabetes and hypertension in sub-Saharan Africa: A systematic review, meta-analysis, and interactive network analysis. PLOS Medicine, 23(8), e1005189. https://doi.org/10.1371/journal.pmed.1005189
  3. Lee, E. K. P., Poon, P., Yip, B. H. K., Bo, Y., Zhu, M.-T., Yu, C.-P., Ngai, A. C. H., Wong, M. C. S., & Wong, S. Y. S. (2022). Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: A meta-analysis involving 27 million patients. Journal of the American Heart Association, 11(17), e026582. https://doi.org/10.1161/JAHA.122.026582
  4. Mackridge, A. J., Wood, E. M., & Hughes, D. A. (2025). Improving medication adherence in the community: A purposive umbrella review of effective patient-directed interventions that are readily implementable in the United Kingdom National Health Service. International Journal of Clinical Pharmacy, 47(3), 640–653. https://doi.org/10.1007/s11096-025-01885-4
  5. Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., Sivaramalingam, B., Iserman, E., Mustafa, R. A., Jedraszewski, D., Cotoi, C., & Haynes, R. B. (2014). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews, (11), CD000011. https://doi.org/10.1002/14651858.CD000011.pub4
  6. Rabbitt, L., Curneen, J., Dennedy, M. C., & Molloy, G. J. (2024). Chemical adherence testing in the clinical management of hypertension: A scoping review. Frontiers in Pharmacology, 15, 1452464. https://doi.org/10.3389/fphar.2024.1452464
  7. Wilhelmsen, N. C., & Eriksson, T. (2019). Medication adherence interventions and outcomes: An overview of systematic reviews. European Journal of Hospital Pharmacy, 26(4), 187–192. https://doi.org/10.1136/ejhpharm-2018-001725
  8. World Health Organization. (2025, September 23). Uncontrolled high blood pressure puts over a billion people at risk [News release]. https://www.who.int/news/item/23-09-2025-uncontrolled-high-blood-pressure-puts-over-a-billion-people-at-risk
  9. Zhou, X., Zhang, X., Gu, N., Cai, W., & Feng, J. (2024). Barriers and facilitators of medication adherence in hypertension patients: A meta-integration of qualitative research. Journal of Patient Experience, 11. https://doi.org/10.1177/23743735241241176

How to cite this page

Choose your referencing style, then copy.

PhD Research Lab Insights. (2026, October 5). Taking blood pressure medicines as prescribed: why decades of adherence research have not closed the control gap. PhD Research Lab. https://www.phdassistance.com/insights/r-and-d/research-gap/hypertension-medication-adherence/

PhD Research Lab Insights. “Taking Blood Pressure Medicines as Prescribed: Why Decades of Adherence Research Have Not Closed the Control Gap.” PhD Research Lab, 5 Oct. 2026, www.phdassistance.com/insights/r-and-d/research-gap/hypertension-medication-adherence. Accessed [access date].

PhD Research Lab Insights (2026) Taking blood pressure medicines as prescribed: why decades of adherence research have not closed the control gap. PhD Research Lab. Available at: https://www.phdassistance.com/insights/r-and-d/research-gap/hypertension-medication-adherence/ (Accessed: [access date]).

PhD Research Lab Insights. “Taking Blood Pressure Medicines as Prescribed: Why Decades of Adherence Research Have Not Closed the Control Gap.” PhD Research Lab. October 5, 2026. https://www.phdassistance.com/insights/r-and-d/research-gap/hypertension-medication-adherence.

PhD Research Lab Insights, ‘Taking Blood Pressure Medicines as Prescribed: Why Decades of Adherence Research Have Not Closed the Control Gap’ (PhD Research Lab, 5 October 2026) <https://www.phdassistance.com/insights/r-and-d/research-gap/hypertension-medication-adherence> accessed [access date].

PhD Research Lab Insights. Taking blood pressure medicines as prescribed: why decades of adherence research have not closed the control gap [Internet]. PhD Research Lab; 2026 Oct 5 [cited [access date]]. Available from: https://www.phdassistance.com/insights/r-and-d/research-gap/hypertension-medication-adherence/

PhD Research Lab Insights, “Taking blood pressure medicines as prescribed: why decades of adherence research have not closed the control gap,” PhD Research Lab, Oct. 5, 2026. [Online]. Available: https://www.phdassistance.com/insights/r-and-d/research-gap/hypertension-medication-adherence. [Accessed: [access date]].

@online{hypertension_medication_adherence_2026,
  author = {{PhD Research Lab Insights}},
  title = {{Taking blood pressure medicines as prescribed: why decades of adherence research have not closed the control gap}},
  organization = {PhD Research Lab},
  date = {2026-10-05},
  url = {https://www.phdassistance.com/insights/r-and-d/research-gap/hypertension-medication-adherence},
  urldate = {[access date]}
}

  • Medication adherence
  • Hypertension
  • Primary care
  • Global health
  • Implementation science
Taking blood pressure medicines as prescribed: why decades of adherence research have not Research gap · Medicine & healthcare
Proposal support